Minimally Invasive Mastectomy Could Achieve Non-inferior Oncological Outcome in Appropriately Selected Patients: Propensity Matched Analysis of the National Cancer Database

2021 ◽  
pp. 000313482110111
Author(s):  
Lifen Cao ◽  
Robert Shenk ◽  
Megan E. Miller ◽  
Christopher Towe

Background Minimally invasive mastectomy (MIM) was emerged as an approach to decrease morbidity and increase patient satisfaction through improved cosmetic results; however, there is a paucity of data regarding the long-term oncologic outcomes of these minimally invasive approaches. Methods Patients who underwent mastectomy procedures were identified in the National Cancer Database (2010-2016). Patients were categorized as MIM or open mastectomy. A 1:1 propensity match was performed to balance the bias on reconstruction, nipple sparing, lymph node procedures, and other confounding factors between the cohorts. Short- and long-term outcomes were compared. Results A total of 328 811 patients met the criteria: 327 643 (99.6%) received open mastectomy and 1168 (.4%) received MIM. Propensity match identified 384 “pairs” of MIM and open mastectomy patients. Among them, MIM was associated with shorter length of stay (LOS) (mean 1.3 vs. 1.06 days, P = .003). No differences were observed in the rates of positive margins, unplanned readmissions, or 90-day mortality between the 2 operative approaches. Overall survival (OS) was equivalent between MIM and open mastectomy patients. Cox proportional hazard regression showed no effect of the procedure performed on OS. Discussion MIM is associated with shorter LOS, and it is non-inferior to open mastectomy in terms of other short-term outcomes and long-term oncologic survival outcomes. These data suggest that MIM may be considered in appropriately selected breast cancer patients as an additional approach to the community.

2020 ◽  
Vol 122 (7) ◽  
pp. 1383-1392
Author(s):  
Michael D. Watson ◽  
Maria R. Baimas‐George ◽  
Kyle J. Thompson ◽  
David A. Iannitti ◽  
Lee M. Ocuin ◽  
...  

2016 ◽  
Vol 42 (11) ◽  
pp. S220
Author(s):  
Esther Platt ◽  
Esther Platt ◽  
Deepali Prakash ◽  
Darmarajah Veeramootoo ◽  
Saj Wajed

2015 ◽  
Vol 33 (28_suppl) ◽  
pp. 60-60 ◽  
Author(s):  
Brittany L. Murphy ◽  
Tanya L. Hoskin ◽  
Judy Caroline Boughey ◽  
Amy C. Degnim ◽  
James W. Jakub ◽  
...  

60 Background: Indications for nipple-sparing mastectomy (NSM) with immediate reconstruction have expanded. For cancer patients, NSM is thought best-suited for early stage patients, with nodal involvement initially viewed as a relative contraindication. We undertook this study to evaluate the use and early outcomes of NSM in node-positive (LN+) breast cancer. Methods: We identified 240 cancers in 226 patients (14 bilateral) scheduled for NSM and operated on at our institution 1/2009-6/2014. Data on intraoperative conversion from NSM, recurrence and follow-up was abstracted from the medical record. Chi-square and long-rank tests were used for statistical analysis. P-values < 0.05 were considered significant. Results: Of 240 cancers, 182 were LN- and 58 were LN+. More LN+ patients had T2/T3 tumors (27/58, 47%) than LN- patients (31/182, 17%), p < 0.0001, but ER and HER2 status was similar. Of 58 LN+ cases, 19 (33%) were cN1 confirmed by positive LN cytology and 39 (67%) were cN0 but LN+ at operation. 10 patients LN+ at diagnosis received neoadjuvant therapy (NT) followed by operation (at which 6 were pLN+ and 4 rendered ypN0); 39 cN0 (4 NT, 35 primary surgery) and 9 cN1 primary surgery patients were pLN+ at operation with a median of 1 LN+. NSM was successful in 13/14 LN+ NT patients (93%) and 39/44 LN+ primary surgery patients (89%), p = 0.64. Six LN+ patients (10%) were converted to skin-sparing mastectomy (SSM) at initial operation based on frozen section pathology (n = 5) or at a second operation (n = 1) vs 13/182 LN- patients (7%), p = 0.44. Among cancer patients treated with NSM, 7 locoregional recurrences (5 in LN+, 2 in LN- patients) occurred at 25 mos median follow-up. 3-year locoregional disease-free estimates were 87% (95% CI 75-100%) for LN+ vs 99% (95% CI 97-100%) for LN- patients, p = 0.007. One nipple-areolar recurrence occurred, in a LN- patient. 3-year breast cancer-specific survival was 97% (95% CI 92-100%) in LN+ vs 99% (95% CI 98-100%) in LN- patients, p = 0.40. Conclusions: Conversion from planned NSM to SSM did not differ significantly between LN+ and LN- patients. Short-term oncologic outcomes were satisfactory. These data suggest that NSM may be appropriate for carefully selected LN+ breast cancer patients.


2020 ◽  
Vol 20 (4) ◽  
pp. 353-358
Author(s):  
Elena Parvez ◽  
Karyne Martel ◽  
Dominique Morency ◽  
Sinziana Dumitra ◽  
Ari N. Meguerditchian ◽  
...  

2018 ◽  
Vol 22 (8) ◽  
pp. 1412-1417 ◽  
Author(s):  
Amit Merchea ◽  
Shahzad M. Ali ◽  
Scott R. Kelley ◽  
Emilie Duchalais ◽  
Jasim Y. Alabbad ◽  
...  

2014 ◽  
Vol 28 (6) ◽  
pp. 649-654 ◽  
Author(s):  
Anudeep Mukkamala ◽  
Chang He ◽  
Alon Z. Weizer ◽  
Khaled S. Hafez ◽  
David C. Miller ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document